Actively Recruiting
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
Led by University of Pennsylvania · Updated on 2025-12-23
90
Participants Needed
2
Research Sites
255 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathies, such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), syndromes of genetic Frontotemporal Lobar Degeneration (genetic FTLD) as well as participants with Parkinson disease (PD), Alzheimer's Disease (AD) and healthy controls. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt), Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WUSTL). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.
CONDITIONS
Official Title
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 40 to 85 years
- Willing and able to provide written informed consent or have a designated study partner to consent and accompany them
- Diagnosed with Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), genetic Frontotemporal Lobar Degeneration (FTLD), Parkinson disease (PD), Alzheimer's Disease (AD), or be a healthy control
- Clinical diagnoses confirmed by consensus committee or video exams within 6 months prior to enrollment (except for AD and healthy controls)
- Brain donation encouraged but not required
You will not qualify if you...
- Pregnant or breastfeeding females (urine pregnancy test required for women of child-bearing potential)
- Parkinsonism forms other than PSP-Richardson Syndrome and Parkinson disease
- History of significant or ongoing alcohol or substance abuse
- Inability to tolerate imaging, arterial line, IV placement, or blood draw as judged by physician
- Contraindications to MRI, including non-compatible implanted medical devices
- Any medical condition or illness that could compromise safety or study participation as judged by physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of California
San Francisco, California, United States, 94143
Actively Recruiting
2
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here